Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Dhooge IJ, De Vos M, Van Cauwenberge PB. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998; 108:250-6; PMID:9473077; http://dx.doi.org/10.1097/00005537-199802000-00017
   PubMed Web of Science ®Google Scholar
• Mashberg A, Samit AM. Early detection, diagnosis, and management of oral and oropharyngeal cancer. CA Cancer J Clin 1989; 39:67-88; PMID:2495159; http://dx.doi.org/10.3322/canjclin.39.2.67
   PubMed Web of Science ®Google Scholar
• Silverman S Jr., Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data–1973 to 1985. J Am Dent Assoc 1990; 120:495-9; PMID:2335670
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001; 98:10290-5; PMID:11517302; http://dx.doi.org/10.1073/pnas.161260098
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT study Investigators. sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009; 100:1502-9; PMID:19459850; http://dx.doi.org/10.1111/j.1349-7006.2009.01200.x
   PubMed Web of Science ®Google Scholar
• Yasuda S, Tsuchiya I, Okada K, Tanaka A, Suzuki T, Sadahiro S, Takeda K, Yamamoto S, Nakui M. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report. Tokai J Exp Clin Med 2012; 37:57-61; PMID:22763829
   PubMedGoogle Scholar
• Dyrskjøt L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, Borre M, Ørntoft TF. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 2012; 107:116-22; PMID:22596240; http://dx.doi.org/10.1038/bjc.2012.215
   PubMed Web of Science ®Google Scholar
• Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O’Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer 2012; 130:1991-2002; PMID:21618523; http://dx.doi.org/10.1002/ijc.26200
   PubMed Web of Science ®Google Scholar
• Ito S, Kawano Y, Katakura H, Takenaka K, Adachi M, Sasaki M, Shimizu K, Ikenaka K, Wada H, Tanaka F. Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung Cancer 2006; 51:79-88; PMID:16225959; http://dx.doi.org/10.1016/j.lungcan.2005.08.012
   PubMed Web of Science ®Google Scholar
• Kim YD, Park HR, Song MH, Shin DH, Lee CH, Lee MK, Lee SY. Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med 2012; 29:656-62; PMID:22294213
   PubMed Web of Science ®Google Scholar
• Montoro JR, Mamede RC, Neder Serafini L, Saggioro FP, Figueiredo DL, Silva WA Jr., Jungbluth AA, Spagnoli GC, Zago MA. Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck 2012; 34:1123-8; PMID:22083937; http://dx.doi.org/10.1002/hed.21880
   PubMed Web of Science ®Google Scholar
• Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K, Kim SU, Ikenaka K. MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 2001; 61:4809-14; PMID:11406556
   PubMed Web of Science ®Google Scholar
• J. Vansteenkiste MZ. A. Linder, J. Dahabre, E. Esteban, W. Malinowski, J. Jassem, B. Passlick, F. Lehmann, V.G. Brichard. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/ II non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings 2007:7554.
   Google Scholar
• Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30; PMID:9935203; http://dx.doi.org/10.1002/(SICI)1097-0215(19990118)80: 2<219::AID-IJC10>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Trefzer U, Jouary T, Robert C, Santinami M, Levchenko E, Smithers B, Testori A, Peeters O, Kirkwood J, Dreno B. FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics. Paper presented at: 6th EADO Congress. 2010 Jun 16-19; Athens, Greece
   Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10:371-4; PMID:19808198; http://dx.doi.org/10.3816/CLC.2009.n.052
   PubMed Web of Science ®Google Scholar
• Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, Prime SS, Teo SH, Silvio Gutkind J, Patel V, et al. Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett 2012; 321:18-26; PMID:22459352; http://dx.doi.org/10.1016/j.canlet.2012.03.025
   PubMed Web of Science ®Google Scholar
• Dhaliwal JS, Shahnaz M, Too CL, Azrena A, Maiselamah L, Lee YY, Irda YA, Salawati M. HLA-A, -B and -DR allele and haplotype frequencies in Malays. Asian Pac J Allergy Immunol 2007; 25:47-51; PMID:17891921
   PubMed Web of Science ®Google Scholar
• Lee LK, Tan EL, Gopala K, Sam CK. Human leukocyte class I antigen alleles A2 and A11 are not associated with nasopharyngeal carcinoma in West Malaysia. Singapore Med J 2007; 48:632-4; PMID:17609824
   PubMedGoogle Scholar
• Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue antigens 2003; 61:403-7.
   PubMed Web of Science ®Google Scholar
• Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 2004; 24:449-61; PMID:15163902; http://dx.doi.org/10.1023/B:JOCI.0000029117.10791.98
   PubMed Web of Science ®Google Scholar
• Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, Kitamura H, Todo S, Nishimura T. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012; 103:150-3; PMID:22221328; http://dx.doi.org/10.1111/j.1349-7006.2011.02106.x
   PubMed Web of Science ®Google Scholar
• Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother 2007; 30:847-54; PMID:18049337; http://dx.doi.org/10.1097/CJI.0b013e318158fcff
   PubMed Web of Science ®Google Scholar
• Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJA. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer 2011; 129:2427-34; PMID:21207413; http://dx.doi.org/10.1002/ijc.25911
   PubMed Web of Science ®Google Scholar
• Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol 2009; 9:57-62; PMID:19104499; http://dx.doi.org/10.1038/nri2471
   PubMed Web of Science ®Google Scholar
• Caruso C, Buffa S, Candore G, Colonna-Romano G, Dunn-Walters D, Kipling D, Pawelec G. Mechanisms of immunosenescence. Immun Ageing 2009; 6:10; PMID:19624841; http://dx.doi.org/10.1186/1742-4933-6-10
   PubMedGoogle Scholar
• Chelimo K, Embury PB, Sumba PO, Vulule J, Ofulla AV, Long C, Kazura JW, Moormann AM. Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One 2011; 6:e24852; PMID:21935482; http://dx.doi.org/10.1371/journal.pone.0024852
   PubMedGoogle Scholar
• Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol 2013; 4:171; PMID:23825474; http://dx.doi.org/10.3389/fimmu.2013.00171
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mohanti BK, Das SN. Ex vivo triggering of T-cell-mediated immune responses by autologous tumor cell vaccine in oral cancer patients. Immunopharmacol Immunotoxicol 2007; 29:95-104; PMID:17464770; http://dx.doi.org/10.1080/089239-70701282742
   PubMed Web of Science ®Google Scholar
• Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003; 25:198-209; PMID:12599287; http://dx.doi.org/10.1002/hed.10195
   PubMed Web of Science ®Google Scholar
• Toyoshima T, Kumamaru W, Hayashida JN, Moriyama M, Kitamura R, Tanaka H, Yamada A, Itoh K, Nakamura S. In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma. Cancer Lett 2012; 322:86-91; PMID:22366580; http://dx.doi.org/10.1016/j.canlet.2012.02.016
   PubMed Web of Science ®Google Scholar
• Hamid S, Lim KP, Zain RB, Ismail SM, Lau SH, Mustafa WM, Abraham MT, Nam NA, Teo SH, Cheong SC. Establishment and characterization of Asian oral cancer cell lines as in vitro models to study a disease prevalent in Asia. Int J Mol Med 2007; 19:453-60; PMID:17273794
   PubMed Web of Science ®Google Scholar
• Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS, Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res 2006; 30:1293-8; PMID:16533527; http://dx.doi.org/10.1016/j.leukres.2006.02.010
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89:293-300; PMID:9048833; http://dx.doi.org/10.1093/jnci/89.4.293
   PubMed Web of Science ®Google Scholar
• Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D’Amaro J, Kenemans P, Melief CJ, Kast WM. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23:1215-9; PMID:7684681; http://dx.doi.org/10.1002/eji.1830230603
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003; 1:14; PMID:14697097; http://dx.doi.org/10.1186/1479-5876-1-14
   PubMedGoogle Scholar
• Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 2010; 210:140-7; PMID:20113933; http://dx.doi.org/10.1016/j.jamcollsurg.2009.10.022
   PubMed Web of Science ®Google Scholar
• Cheong SC, Chandramouli GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathan R, Prime SS, Teo SH, Patel V, et al. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol 2009; 45:712-9; PMID:19147396; http://dx.doi.org/10.1016/j.oraloncology.2008.11.002
   PubMed Web of Science ®Google Scholar